Compare PW & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PW | ENVB |
|---|---|---|
| Founded | 1967 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 3.0M |
| IPO Year | N/A | N/A |
| Metric | PW | ENVB |
|---|---|---|
| Price | $1.04 | $5.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.9M |
| Earning Date | 10-24-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,075,489.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $4.55 |
| 52 Week High | $1.96 | $96.30 |
| Indicator | PW | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 59.08 | 47.03 |
| Support Level | $0.91 | $4.55 |
| Resistance Level | $1.10 | $5.79 |
| Average True Range (ATR) | 0.12 | 1.29 |
| MACD | 0.01 | -0.25 |
| Stochastic Oscillator | 78.66 | 5.75 |
Power REIT is an internally managed real estate investment trust (REIT) that owns a portfolio of real estate assets related to transportation, energy infrastructure, and Controlled Environment Agriculture (CEA) in the United States. Its investment portfolio comprises solar farm lands, railroad real estate, and various Controlled Environment Agriculture properties in the form of greenhouses for the cultivation of food and cannabis. In addition, the company is focused on opportunities in the form of investing in distressed situations, including debt and other types of secured interests in real estate, distressed properties, and real estate-related companies.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.